Actavis divests its stake in PLIVA
24-Oct-2006
The shareholding was a strategic stake acquired by Actavis to support its proposed bid for PLIVA. Following Actavis' Board's decision not to increase its offer above the price of HRK820 per share being offered by Barr Pharmaceuticals for PLIVA, Actavis has withdrawn its proposal and no longer sees the benefits of retaining its shareholding in PLIVA.
Organizations
PLIVA
Barr Pharmaceuticals
Actavis
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.